CAMBRIDGE, Mass., May 19, 2022
/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX)
(Theseus or the Company), a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients through
the discovery, development and commercialization of
transformative targeted therapies, today announced
that the company will participate virtually in the H.C.
Wainwright Global Investment Conference taking place May 23-26, 2022 and in-person in the Jefferies
Healthcare Conference taking place June
8-10, 2022.
Presentation Details:
Event: H.C.
Wainwright Global Investment Conference
Date / Time: Monday, May
23rd – Thursday, May
26th, 2022, on demand
Format: Virtual Presentation
Event: Jefferies Healthcare Conference
Date / Time: Thursday, June
9th, 2022, at 4:30pm
ET
Format: Live Fireside Chat
A live webcast will be available in the Events section of the
company's investor relations website
at ir.theseusrx.com and archived for 30 days following
the presentations.
Management will also be participating in one-on-one investor
meetings throughout the conferences. Investors interested in
scheduling a meeting with the Theseus management team should
contact their H.C. Wainwright or Jefferies representatives.
About Theseus Pharmaceuticals, Inc.
Theseus is a
clinical-stage biopharmaceutical company focused on improving the
lives of cancer patients through the discovery, development and
commercialization of transformative targeted therapies. Theseus is
working to outsmart cancer resistance by developing pan-variant
tyrosine kinase inhibitors (TKIs) to target all known classes of
cancer-causing and resistance mutations that lead to variants in a
particular protein in a given type of cancer. Theseus' lead product
candidate, THE-630, is a pan-variant KIT inhibitor for the
treatment of patients with advanced gastrointestinal stromal tumors
(GIST), whose cancer has developed resistance to earlier lines of
kinase inhibitor therapy. Theseus is also developing a
fourth-generation, selective epidermal growth factor receptor
(EGFR) inhibitor for C797S-mediated resistance to first- or
later-line osimertinib treatment in patients with non-small cell
lung cancer (NSCLC). For more information,
visit www.theseusrx.com.
Media Contact
Amy Jobe,
Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
Investor Contacts
Christen
Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com
View original
content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-in-upcoming-investor-conferences-301550659.html
SOURCE Theseus Pharmaceuticals